Marta Pla Verge

Marta Pla Verge

Auto-generated profile, based on publicly available information

Marta Pla Verge

Resistell AG

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 March 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
ASAlexander Sturm
Alexander Sturm
GJGrzegorz Jóźwiak
Grzegorz Jóźwiak
MVMarta Pla Verge
Marta Pla Verge
LMLaura Munch
Laura Munch
GCGino Cathomen
Gino Cathomen
DCDanuta Cichocka
Danuta Cichocka
Antimicrobial resistance (AMR) is a major public health threat, reducing treatment options for infected patients. AMR is promoted by a lack of access to rapid antibiotic susceptibility tests (ASTs). Accelerated ASTs can identify effective antibiotics for treatment in a timely and informed manner. We describe a rapid growth-independent phenotypic AST that uses a nanomotion technology platform to measure bacterial vibrations. Machine learning techniques are applied to analyze a large dataset encompassing 2762 individual nanomotion recordings from 1180 spiked positive blood culture samples covering 364Escherichia coliandKlebsiella pneumoniaeisolates exposed to cephalosporins and fluoroquinolones. The training performances of the different classification models achieve between 90.5 and 100% accuracy. Independent testing of the AST on 223 strains, including in clinical setting, correctly predict susceptibility and resistance with accuracies between 89.5% and 98.9%. The study shows the potential of this nanomotion platform for future bacterial phenotype delineation.

30 June 2026 in Microbiology Spectrum
Verified
Journal Article
Open access
MVMarta Pla Verge
Marta Pla Verge
JWJan Winnicki
Jan Winnicki
ALAmanda Luraschi-Eggemann
Amanda Luraschi-Eggemann
GJGrzegorz Jozwiak
Grzegorz Jozwiak
KFKatja Fromm
Katja Fromm
ASAlexander Sturm
Alexander Sturm
Carbapenem-resistant Acinetobacter baumannii (CRAB) represents a major clinical threat, underscoring the urgent need for both new antibiotics and rapid antimicrobial susceptibility testing (AST) methods that can inform treatment. Here, we describe a susceptibility assessment that combines nanomotion technology with machine learning (ML) to rapidly classify responses to zosurabalpin (ZAB), the first-in-class antibiotic targeting the LptB₂FGC complex of the lipopolysaccharide transport pathway in A. baumannii . Nanomotion recordings from five A. baumannii strains spanning a wide range of minimum inhibitory concentrations (MICs) were measured at multiple ZAB concentrations. A logistic regression ML model was trained using a labeling strategy that categorized recordings as susceptible or non-susceptible based on strain MICs obtained by reference methods and antibiotic concentrations measured. This model, built on four quantile features, achieved >90% accuracy compared with susceptibility responses. These results highlight four key advances: (i) nanomotion-based AST can deliver reliable phenotypic classification for new antibiotics before clinical breakpoints are available, (ii) accurate results can be obtained within only 2 h, (iii) the method extends nanomotion’s applicability to high-priority pathogens, such as CRAB, and (iv) the nanomotion response can reflect early cellular changes that precede a measurable decline in viability, suggesting that susceptibility may be detected before killing becomes apparent by conventional methods. Together, this work establishes nanomotion-ML AST as a promising diagnostic platform to support the evaluation and future integration of novel drugs into clinical practice, advancing next-generation rapid AST workflows against critical multidrug-resistant pathogens. IMPORTANCE: This study demonstrates a rapid, nanomotion-based approach with potential to inform antibiotic susceptibility assessment for Acinetobacter baumannii infections. By combining nanomotion technology with quantitative machine-learning-assisted signal analysis, susceptibility to the novel antibiotic zosurabalpin, which is currently in clinical development, could be determined within 2 h. The assay reliably distinguished susceptible from non-susceptible phenotypes across strains with different MICs and in both standard and horse serum-supplemented media. Notably, the nanomotion signature reflected early cellular responses that preceded a measurable decline in viability by conventional methods. Together, these features provide rapid phenotypic insights that may support future development of timely, targeted therapy decisions. The findings highlight nanomotion-based antimicrobial susceptibility testing as a promising tool to accelerate diagnostic readiness for new antibiotics and improve treatment management in infections caused by multidrug-resistant A. baumannii .